Table 2.
Baseline clinical characteristics.
| Variable | Number of subjects (sample size = 3173) | Weighted percentages |
| Symptoms | ||
| Asymptomatic | 1001 | 30.9 |
| Lower urinary alone | 1832 | 58.4 |
| Systemic | 340 | 10.7 |
| Comorbid conditions | ||
| None | 1211 | 37.2 |
| 1 | 1008 | 32.5 |
| 2 | 520 | 16.3 |
| 3+ | 434 | 13.9 |
| Health status | ||
| Excellent | 534 | 16.9 |
| Good | 2104 | 66.2 |
| Fair or poor | 500 | 15.9 |
| Unknown | 35 | 1.0 |
| PSA (ng/ml) | ||
| <4 | 294 | 8.8 |
| ≥ 4 | 2675 | 84.5 |
| Unknown | 204 | 6.7 |
| Digital rectal examination | ||
| Abnormal | 1741 | 54.8 |
| Normal | 1033 | 33.2 |
| Unknown | 399 | 12.0 |
| Gleason score | ||
| 2 – 4 | 481 | 13.9 |
| 5 – 7 | 2029 | 65.1 |
| 8 – 10 | 373 | 11.6 |
| Unknown | 290 | 9.4 |
| Tumor stage | ||
| Local | 2796 | 88.7 |
| Regional | 126 | 3.7 |
| Advanced | 251 | 7.6 |
Legend: PSA = prostate-specific antigen